Roivant unveils new subsidiary on deal with Ligand
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) granted exclusive, worldwide rights for diabetes candidate RVT-1502 (formerly LGD-6972) to the newly created Metavant Sciences subsidiary of Roivant Sciences GmbH (Basel, Switzerland). Roivant has established at least six subsidiaries, which it calls "vants," focused on drug development.
In September, Ligand reported RVT-1502 met the primary endpoint of...
Read the full 237 word article
User Sign in
Trial Subscription
Get a 4-week free trial subscription to BioCentury Extra
Article Purchase
$50 USD
